Semler Scientific Inc. (NASDAQ:SMLR) Given Consensus Recommendation of “Moderate Buy” by Analysts

Semler Scientific Inc. (NASDAQ:SMLR) has earned a consensus rating of “Moderate Buy” from the five analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $74.25.

Several analysts have issued reports on the stock. Benchmark decreased their price objective on shares of Semler Scientific from $101.00 to $86.00 and set a “buy” rating for the company in a research note on Tuesday, September 23rd. Cantor Fitzgerald reduced their price target on Semler Scientific from $61.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday, August 6th. Maxim Group decreased their price target on Semler Scientific from $95.00 to $80.00 and set a “buy” rating for the company in a research note on Friday, September 19th. Finally, Weiss Ratings downgraded Semler Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday.

Institutional Investors Weigh In On Semler Scientific

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp grew its stake in Semler Scientific by 23.1% in the 1st quarter. Bank of New York Mellon Corp now owns 20,454 shares of the company’s stock worth $740,000 after acquiring an additional 3,843 shares in the last quarter. Cetera Investment Advisers boosted its holdings in shares of Semler Scientific by 26.7% in the first quarter. Cetera Investment Advisers now owns 22,654 shares of the company’s stock valued at $820,000 after purchasing an additional 4,775 shares during the period. Pacer Advisors Inc. bought a new position in Semler Scientific in the first quarter worth approximately $1,874,000. Charles Schwab Investment Management Inc. increased its holdings in Semler Scientific by 226.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 158,576 shares of the company’s stock worth $5,740,000 after purchasing an additional 109,951 shares during the period. Finally, Deutsche Bank AG lifted its holdings in shares of Semler Scientific by 82.0% in the 1st quarter. Deutsche Bank AG now owns 4,893 shares of the company’s stock worth $177,000 after buying an additional 2,204 shares during the period. Institutional investors own 49.37% of the company’s stock.

Semler Scientific Stock Up 3.0%

Shares of SMLR opened at $19.02 on Friday. The company has a quick ratio of 1.95, a current ratio of 1.97 and a debt-to-equity ratio of 0.21. The business has a fifty day moving average of $26.60 and a 200 day moving average of $32.73. The company has a market cap of $288.34 million, a PE ratio of 6.84 and a beta of 1.44. Semler Scientific has a 52-week low of $17.41 and a 52-week high of $81.56.

Semler Scientific (NASDAQ:SMLR) last announced its earnings results on Wednesday, November 12th. The company reported $1.07 earnings per share for the quarter, beating the consensus estimate of ($0.14) by $1.21. Semler Scientific had a net margin of 130.80% and a return on equity of 34.21%. The business had revenue of $7.49 million for the quarter, compared to the consensus estimate of $7.87 million.

Semler Scientific Company Profile

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition.